cagrilintide/semaglutide (CagriSema)events and moves- 16 Nov 2026 Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek® own move +0.4%, next session -0.8%
- 15 Nov 2026 Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026 own move +0.4%, next session -0.8%
- 14 Nov 2026 Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology own move +0.4%, next session -0.8%
- 29 Oct 2026 Novo to present new CagriSema and Wegovy® data at ObesityWeek® 2026, including data on treatment experience with Wegovy® pill in the real world own move -0.2%, next session +1.7%
- 20 Oct 2026 Novo's CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting own move +0.0%, next session -0.2%
- 30 Sep 2026 Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026 own move +0.3%, next session -0.0%
- 21 Sep 2026 Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial own move -8.3%, next session -1.5%
- 4 Aug 2026 REIMAGINE 4: CagriSema non-inferior to tirzepatide on weight, not on HbA1c (mixed) own move -5.9%, next session -0.7%
- 7 Jun 2026 Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 own move -4.3%, next session +1.6%
- 27 May 2026 Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions own move +0.6%, next session +0.8%
- 23 Feb 2026 Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved own move -17.5%, next session -2.2%
- 2 Feb 2026 Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial own move -1.5%, next session -13.6%
- 18 Dec 2025 Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management own move -0.4%, next session +0.3%
- 6 Nov 2025 Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek® own move -4.2%, next session -1.9%
- 22 Jun 2025 CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM own move -5.2%, next session +0.2%
| 16 | 26% |
Semaglutide (Ozempic) (Ozempic)events and moves- 29 Sep 2026 Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD own move -0.7%, next session +0.3%
- 15 Sep 2026 Beyond "Ozempic Face": New Review Finds Nutrition May Be the Missing Piece in GLP-1 Skin Changes own move -2.1%, next session -2.0%
- 12 Sep 2026 Meant Health Expands Telehealth Access to FDA-Approved GLP-1 Prescriptions, Including Ozempic® own move -0.6%, next session -2.1%
- 19 Jun 2026 ProGen pits GLP-1/GLP-2 drug against Ozempic in global phase 2b trial own move +5.8%, next session +1.9%
- 1 May 2026 Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US own move +4.5%, next session +1.5%
- 24 Feb 2026 Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access own move -2.2%, next session -1.1%
- 9 Feb 2026 Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic® own move +4.5%, next session +0.1%
- 20 Jan 2026 Novo Nordisk introduces "There's Only One Ozempic®" campaign, reuniting Justin Long and John Hodgman own move -2.4%, next session -4.1%
- 17 Nov 2025 Novo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 per month own move +0.5%, next session -2.5%
- 18 Sep 2025 Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study own move +6.1%, next session -0.6%
- 20 Aug 2025 Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025 own move -1.4%, next session +2.5%
- 18 Aug 2025 Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines own move +2.8%, next session +1.3%
- 23 Jun 2025 Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities own move -5.2%, next session +0.2%
- 25 Apr 2025 Novo Nordisk protects US patients with legal wins against compounders, including ruling that permanently prohibits compounding pharmacy from selling illegitimate, knockoff Wegovy® or Ozempic® own move -1.4%, next session +0.5%
- 29 Mar 2025 Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025 own move -0.8%, next session -0.2%
| 17 | 5% |
Semaglutide (Wegovy) (Wegovy)events and moves- 17 Nov 2026 Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards own move -0.8%, next session -0.9%
- 14 Nov 2026 Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026 own move +0.4%, next session -0.8%
- 12 Nov 2026 Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine own move -0.5%, next session +1.9%
- 29 Oct 2026 Novo to present new CagriSema and Wegovy® data at ObesityWeek® 2026, including data on treatment experience with Wegovy® pill in the real world own move -0.2%, next session +1.7%
- 28 Oct 2026 Andel Collaborates With Novo To Bring Wegovy® Injection and Wegovy® Pill Direct-to-Employers own move -1.3%, next session -0.2%
- 30 Sep 2026 Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill own move +0.3%, next session -0.0%
- 16 Sep 2026 Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026 own move -2.0%, next session +2.9%
- 7 Sep 2026 STEP Young Phase 3 meets its primary endpoint own move -0.6%, next session -1.0%
- 15 Jul 2026 Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved own move +3.0%, next session -0.4%
- 11 Jun 2026 Wegovy pill (semaglutide tablets) approved in the UK own move +1.9%, next session -0.0%
- 3 Jun 2026 Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care own move -2.9%, next session +1.1%
- 22 May 2026 Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1) own move +0.1%, next session -0.8%
- 13 May 2026 Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026 own move -0.4%, next session -2.7%
- 12 May 2026 Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity own move -0.7%, next session -0.4%
- 12 May 2026 Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity own move -0.7%, next session -0.4%
| 34 | 4% |
zenagamtideevents and moves- 16 Nov 2026 Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek® own move +0.4%, next session -0.8%
- 24 Aug 2026 DehydraTECH™-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria’s 2026 Animal Study #2 own move +0.3%, next session +3.4%
- 5 Jun 2026 Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026 own move -2.4%, next session -4.3%
- 27 May 2026 Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions own move +0.6%, next session +0.8%
- 25 Nov 2025 Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes own move +2.4%, next session +3.7%
- 20 Jun 2025 Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet own move +0.2%, next session -5.2%
- 20 Jun 2025 Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025 own move +0.2%, next session -5.2%
- 12 Jun 2025 Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development own move +2.2%, next session -1.0%
- 24 Jan 2025 Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity own move +8.3%, next session -2.8%
| 8 | 3% |
Semaglutide (Wegovy tablets) (Wegovy)events and moves- 17 Nov 2026 Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards own move -0.8%, next session -0.9%
- 14 Nov 2026 Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026 own move +0.4%, next session -0.8%
- 12 Nov 2026 Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine own move -0.5%, next session +1.9%
- 2026-07 EMA/EC approval: Wegovy pill (once-daily oral semaglutide) for weight management own move +1.2%, next session +0.8%
- 11 Jun 2026 Wegovy pill approved in the UK own move +1.9%, next session -0.0%
- 19 Mar 2026 FDA approves Wegovy HD (semaglutide) injection 7.2 mg own move -0.6%, next session -0.6%
- 22 Dec 2025 FDA approves Wegovy pill for weight management own move -0.2%, next session +7.5%
- 22 Dec 2025 FDA approval: Wegovy tablets (oral semaglutide 25 mg): reduce body weight in adults with overweight or obesity, and reduce the risk of major adverse cardiovascular events own move -0.2%, next session +7.5%
- 26 Nov 2025 sNDA submitted for Wegovy 7.2 mg own move +3.7%, next session +1.8%
- 15 Aug 2025 FDA accelerated approval of Wegovy for MASH own move +1.2%, next session +2.8%
- 2 May 2025 FDA accepts NDA for oral Wegovy (semaglutide) 25 mg own move +4.2%, next session +0.1%
| 10 | 1% |
insulin icodec (Awiqli)events and moves- 23 Oct 2026 Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes own move +0.2%, next session +0.2%
- 11 Aug 2026 Novo Nordisk's Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US own move -0.9%, next session -1.9%
- 26 Mar 2026 FDA approval: Awiqli is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. own move +0.5%, next session +0.7%
- 26 Mar 2026 FDA approves Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes own move +0.5%, next session +0.7%
- 26 Mar 2026 Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes own move +0.5%, next session +0.7%
- 11 Jul 2024 Novo Nordisk: Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec own move -2.8%, next session +1.0%
| 4 | shown from 8 days |
cagrilintideevents and moves | 3 | shown from 8 days |
UBT251events and moves | 3 | shown from 8 days |
IcoSema (Kyinsu)events and moves | 3 | shown from 8 days |
Semaglutide (Rybelsus) (Rybelsus)events and moves | 3 | shown from 8 days |
Etavopivatevents and moves | 2 | shown from 8 days |
CDR132Levents and moves | 1 | shown from 8 days |
Ziltivekimabevents and moves | 1 | shown from 8 days |
Coramitugevents and moves | 1 | shown from 8 days |
dasiglucagon (Zegalogue)events and moves | 1 | shown from 8 days |
zaltenibartevents and moves | 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 6% |
| Other company news (earnings, financing, releases naming no asset) | — | 36% |
| Sessions with no dated event | — | 20% |